{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:spironolactone",
  "owner": "cardio",
  "kind": "drug",
  "slug": "spironolactone",
  "name": "Spironolactone",
  "aliases": [
    "Aldactone"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Spironolactone, sold as Aldactone, is an aldosterone antagonist, a medicine taken by mouth that blocks the hormone aldosterone. The US label read, for Aldactone tablets, lists four uses: heart failure with reduced ejection fraction in people with the more severe symptom classes (NYHA class III to IV), to increase survival, manage swelling and reduce hospital stays for heart failure; add-on treatment of high blood pressure; swelling in adults with cirrhosis of the liver or in the nephrotic syndrome when the measures the label names first have not worked well enough; and primary hyperaldosteronism.",
  "summary_technical": "RxNorm ingredient 9997; UNII 27O7W4T232. MeSH descriptor D013148 is Spironolactone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Pfizer Laboratories Div Pfizer Inc label for Aldactone tablets, application NDA012151, effective 2025-11-28 in openFDA. The plan row pointed at a spironolactone and hydrochlorothiazide combination label; the single-ingredient brand label replaces it. The combination product (Aldactazide, NDA012616) and generic labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "9997",
      "normalized_value": "9997",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "27O7W4T232",
      "normalized_value": "27O7W4T232",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D013148",
      "normalized_value": "D013148",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart",
        "blood-vessels"
      ],
      "condition-area": [
        "heart-failure",
        "hypertension"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says spironolactone and its active metabolites are specific pharmacologic antagonists of aldosterone."
  },
  "content_digest": "623116861745a51c1146b1091d7a921d11dfd2f1ae34d642fa946fff70c173a3",
  "review": {
    "content_digest": "623116861745a51c1146b1091d7a921d11dfd2f1ae34d642fa946fff70c173a3",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-spironolactone-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:spironolactone",
      "category": "descriptive",
      "statement": "The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.",
      "context": {
        "id": "cardio:ctx-fda-aldactone-label-us",
        "label": "Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets",
        "recipient": "unknown",
        "population": "Patients described in the indications section of the label: people with NYHA class III to IV heart failure and reduced ejection fraction, people with hypertension, adults with edema from cirrhosis of the liver or the nephrotic syndrome, and people with primary hyperaldosteronism. The passages read do not state an age range for each use.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated for each use in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with NYHA Class III to IV heart failure and reduced ejection fraction",
            "Patients with hypertension who are not adequately controlled on other agents",
            "Patients with edema in cirrhosis of the liver or the nephrotic syndrome",
            "Patients with primary hyperaldosteronism"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.1 Heart Failure",
          "applicability_note": "Label passage quoted in the research quote table (LB-05, LB-10).",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.2 Hypertension",
          "applicability_note": "Label passage quoted in the research quote table (LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome",
          "applicability_note": "Label passage quoted in the research quote table (LB-07, LB-11).",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.4 Primary Hyperaldosteronism",
          "applicability_note": "Label passage quoted in the research quote table (LB-08, LB-12).",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20251128.",
          "snapshot": {
            "id": "cardio:openfda-label-aldactone-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91",
            "source_effective_date": "2025-11-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-aldactone",
            "source_type": "regulator",
            "title": "openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-spironolactone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "6970170dab7b7ad9046e93d07ee5eb18790c3521235e167feb94f08d9d69d6cf",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-spironolactone-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Spironolactone is an aldosterone antagonist (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:mineralocorticoid-receptor-antagonists",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-9997-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists NYHA class III to IV heart failure with reduced ejection fraction as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:hfref",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-spironolactone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists add-on treatment of hypertension as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-spironolactone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists primary hyperaldosteronism as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:primary-aldosteronism",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-spironolactone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The mineralocorticoid receptor antagonist class is one of the four classes of the heart failure regimen",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:hfref-four-medicine-regimen",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/spironolactone/",
  "context_path": "api/v1/context/cardio--spironolactone.md"
}
